RBC Capital raised the firm’s price target on Tenet Healthcare (THC) to $189 from $183 and keeps an Outperform rating on the shares. The company reported strong Q1 results with adjusted EBITDA coming in nearly 17% ahead of the firm’s expectations, and RBC sees a significant opportunity for Tenet to outperform the company’s guidance range given significant operating leverage on solid topline growth, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target raised to $230 from $217 at UBS
- Tenet Healthcare price target raised to $180 from $165 at Guggenheim
- Tenet Healthcare price target raised to $171 from $161 at Barclays
- Tenet Healthcare’s Strategic Expansion and Strong Financial Performance Highlighted by Conservative Guidance and Robust Margins
- Tenet Healthcare Reports Strong Q1 2025 Results